Meeting
2018 Genitourinary Cancers Symposium
Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients.
Authors
Ricardo Romao Nazario Leao
University Health Network, Toronto, ON, Canada
Ricardo Romao Nazario Leao , Ton Van Agthoven , Arnaldo Figueiredo , Kamel Fadaak , Pedro Castelo-Branco , Michael A.S. Jewett , Joan Sweet , Ardalan Ahmad , Lynn Anson-Cartwright , Philippe L. Bedard , Peter W. M. Chung , Aaron Richard Hansen , Padraig Richard Warde , Martin O'Malley , Leendert Looijenga , Robert James Hamilton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Penile, Urethral, and Testicular Cancers
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 546)
DOI
10.1200/JCO.2018.36.6_suppl.546
Abstract #
546
Poster Bd #
A3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.
First Author: Ahmed Bilal Khalid
Poster
2022 ASCO Genitourinary Cancers Symposium
Viable germ cell tumor and teratoma can be distinguished from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens by a combination of microRNA-371a-3p and 375-5p.
First Author: Tim Nestler
Poster
2020 Genitourinary Cancers Symposium
Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.
First Author: Nirmish Singla
Poster
2022 ASCO Annual Meeting
Management of residual nonretroperitoneal disease in nonseminomatous germ-cell tumors (NSGCT).
First Author: Jennifer King